Vector VestAdvertisement SPDR Advertisement
Home > Boards > US OTC > Medical - Healthcare >

Quture International, Inc. (QUTR)

QUTR RSS Feed
Add QUTR Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator inforthemoney2
Search This Board:
Last Post: 1/26/2015 1:28:13 PM - Followers: 57 - Board type: Free - Posts Today: 8

http://images.investorshub.advfn.com/images/uploads/2011/12/19/xkxznQUTURE_PIC.jpg

Quture International, Inc

OTCQB Logo

Contact Info

     

Quture International, Inc.
200 Magnolia Avenue
Daytona Beach, FL 32114 

 

Phone: (407) 377-6649

Email: info@quture.com






 

View larger map












Share Structure
OS: 2.5B Shares.
FLOAT: 375M Shares
(2.5B x .85 = 2.125B, 2.5M - 2.125B = 375M)

 

SHARES FROM THE MERGER ARE RESTRICTED

The securities described in Item 1.01 above were offered and sold in reliance upon exemptions from registration pursuant to Section 4(2) under the Securities Act.  At the time of their issuance, the securities will be deemed to be restricted securities for purposes of the Securities Act, and the certificates representing the securities shall bear legends to that effect.  The securities may not be resold or offered in the United States without registration or an exemption from registration.


INSIDERS OWN 85% (AUG 9, 2011)
As a result of the Exchange, Quture became a wholly-owned subsidiary of the Registrant. Following the consummation of the Exchange, the shareholders of Quture will beneficially own approximately eighty-five percent (85%) of the issued and outstanding Common Stock of the Registrant.

So On TOP of the Restriction these shares can only be sold per insider trading rules which is something along the lines of 1% of the volume of the previous 10 trading days, etc)

 


ABOUT  QUTURE

Quture is an emerging healthcare knowledge solution company positioned to transform health and healthcare by developing the standard in measuring clinical performance. The Company's products and services will become the essential technology and tool to improve care and health, while reducing costs. The demand to measure performance is coming from all stakeholders in healthcare involved in both payment and delivery. Measuring performance is now mandatory and is the new foundation of how providers are reimbursed, granted privileges to practice in hospitals, and, in the near future, selected by patients for their care.

Quture is not a software company. Quture is the company that makes the best software in the world better. We know what to find, where to find it, and what to do with it once you find that data in disparate electronic data sources in healthcare organizations. The Company licenses the application of performance measures delivered in a software platform creating the most powerful clinical knowledge database in the world. Quture knows what payers want to pay for, and what they do not want to pay for, and the clinical knowledge to support payment systems while improving care.

Quture's mission statement is to become the Gold Standard in Healthcare Performance Measurement. Quture provides healthcare organizations, insurers, government payers, and other stakeholders in the healthcare community with performance measurement tools and data sets. Industry experts agree that these performance measures are the "transformative tool" that reduce medical cost and improve quality of care. Q'uture's management team has 35 years of experience and a long history of working with many of the nation's leading healthcare institutions as a leader and innovator in measuring clinical performance. Quture plans include developing a revolutionary solution to effectively and efficiently measure clinical performance from multiple vendor databases



G. Landon Feazell, Chairman & CEO

Landon Feazell is Chairman and Chief Executive Officer of Quture, Inc., positioned to become a major force in the transformation of health care and personal health. The company leverages over 35 years of measuring performance & outcomes and improving clinical quality and patient safety to anticipate the needs of providers to chart the future of quality in health care. The core capabilities of Quture are embedded in software and technology to convert data to clinical knowledge to achieve evidence-based, predictive clinical care. Mr. Feazell is nationally recognized for his leadership, innovation, and expertise in measuring clinical performance, pioneering proactive clinical risk management and patient safety and physician peer review processes. His companies have developed and implemented systems and processes in hundreds of hospitals, hospital corporations and trusts, university health systems, health maintenance organizations, large and small physician practices, federal and state governmental agencies, and health and liability insurance companies throughout the United States.

Mr. Feazell received a Bachelor of Science degree in zoology from Duke University (1965). His extensive graduate studies are in medical sciences at the West Virginia University Medical Center (1965-1967), where he was a teaching fellow, conducting research in mycology and its relationship to leukemia and preventive medicine under the direction of Ernest W. Chick, M.D., Ph.D. His graduate studies further included law at the University of Denver, College of Law (1967-1970), where he was student assistant to the deans. He served as Chairman of the National Conference of Law Reviews (1968-69) and after graduation has served as Chairman of the Board Council of Community Mental Health Centers and chaired board training grants for these centers for a federal region. His community service includes chairing many public education initiatives for Jefferson County Board of Education and successful political campaign cabinets for Governor and United States Senator in Colorado. He is widely published in professional articles, and he lectures, teaches, and participates on national expert panels at universities, professional organizations, private corporations, and forums and seminars and has taught at the undergraduate and graduate level at several universities.


 

Janice J. Ophoven, MD, Associate Medical Director (QualOptima)

Dr. Janice Ophoven is a pediatric forensic pathologist with over thirty years of clinical, administrative and quality improvement experience. She is board certified in Pathology, Forensic Pathology, Quality Assurance and Utilization Review. Dr. Ophoven has focused her clinical practice on understanding child abuse and injury to children.

Dr. Ophoven is an internationally recognized and a court-certified medical expert in pediatric forensic pathology. She has consulted and/or testified in civil and criminal cases in the US and abroad for both defense and prosecution when injury or death to a child has occurred. For these cases and as a consultant to Medical Examiners/coroners, physicians, law enforcement, and legal professionals she has been asked to determine the cause and manner of a child's injury or death.

She is also a consultant and nationally recognized speaker and educator on Forensic Pathology as well as on quality improvement of health care systems. She has worked with physicians, clinicians and hospital systems at organizations such as, Children's Hospital-St. Paul, MN; and Allina Health System, MN: Montefiore Hospital (Albert Einstein University), NY to improve quality system-wide.

Through her years of experience, Dr. Ophoven has pioneered an innovative and successful evidence-based model that draws on medical science and practicing clinicians to identify risk and challenge barriers to successful medical care.

In 1981, Dr. Ophoven founded her firm specializing in pediatric forensic pathology services. Her work has included cases of Munchausen's Syndrome By Proxy (MSBP), infanticide, sexual misuse, infant apnea/SIDS, suffocation, and accidental and inflicted head trauma. Her work requires both in-depth knowledge of medical sciences and forensics including: General Pediatric Pathology and Laboratory Medicine, Developmental and Gestational Pathology, as well as Pediatric Autopsy and Injury Analysis, Pediatric Laboratory Medicine, Pediatric Hematopathology, and Pediatric Pulmonary Disease.


 

Keith Candiotti, MD, Associate Medical Director (QSurg)

  • Chief of the Division of Perioperative Medicine, Department of Anesthesiology, University of Miami Miller School of Medicine
  • Vice Chairman of Clinical Research, Department of Anesthesiology, University of Miami School of Medicine
  • Associate professor of anesthesiology
  • Miami, Florida

Dr. Keith Candiotti is a graduate of the University of Miami Miller School of Medicine, where he completed a residency in internal medicine in 1992 and a residency in anesthesiology in 1994 and went on to join the Department of Anesthesiology. He currently serves as Chief of the Division of Perioperative Medicine and Vice Chairman of Clinical Research within the department. Additionally, he has coappointments in the departments of Internal Medicine, Urology, and Obstetrics and Gynecology.

Dr. Candiotti has conducted numerous clinical trials, including US Food and Drug Administation studies in the areas of postoperative nausea and vomiting (PONV), pain, consciousness monitoring, and other various clinical areas. His personal research interests are in the areas of perioperative inflammatory responses; pharmacogenomics and how it relates to pain and perioperative outcomes, PONV, and preoperative evaluation; and the management of patients exposed to weapons of mass destruction. He is a member of the American Society of Anesthesiologists Committee on Research and was recently appointed as Chairman of the Society of Ambulatory Anesthesia Research Committee.

Dr. Candiotti has published numerous articles and abstracts at various medical meetings. He currently lectures both in the United States and around the world on topics related to his areas of interest.


 

Judith K. Daugherty, RN, PhD, Director, Multi-Disciplinary Clinical Content

Dr. Daugherty co-founded Excelcare, Inc., in 1984 and serves as its President/CEO. The Excelcare product is the leading nursing care plan and documentation system for nursing expected outcomes. The software introduced the innovative nursing software technology for five functions: Planning/Clinical Pathways, Documenting, Quality Management, Staffing and Costing. The Excelcare product has been successfully marketed and implemented in the USA, Australia, Asia, and Europe. Dr. Daugherty has served in a consultation role for Lockheed Martin Federal Systems Health Division, CareGroup System (Boston) and Price Waterhouse Senior Management Consultant in hospital and nursing engagements. Prior to Excelcare, she was Associate Administrator Mercy Hospital (PA). She has organized, sponsored and/or presented at domestic and international professional education seminars for all levels of healthcare professionals, as well as being Adjunct Professor (Nursing): Hunter College (NY, NY) and University of Pittsburgh (PA) and Professor (Masters Nursing Administration Program): Duquesne University (Pittsburgh, PA). Her community service includes being Past Chairman of PA Board of Directors, American Heart Association.


 


RECENT NEWS:

Tuesday, November 13, 2012

     .  
Quture Recruits Healthcare Visionary and Accomplished Expert to Strengthen Distinguished Management Team     MWUS(Tues, Nov 13)

Monday, August 27, 2012

       .
Quture/TCLN QualOptima Product Business Case Expands Focus to Patient-Centered Personalized Medicine Marketwire(Mon, Aug 27)

Wednesday, August 8, 2012  

       .
Quture/TCLN QualOptima Product on Target With Hospital Urgent Needs to Acquire Clinical Analytics Tools  Marketwire(Wed, Aug 8)

Monday, July 30, 2012

     .
Quture/TCLN Announces Successful Completion Of Interdisciplinary Product At Niagra Falls Memorial Hospital Preparing For Comm..  PRNUS(Mon, Jul 30)


Wednesday, July 11, 2012

     .
Quture/TCLN & Springhill Medical Center Jointly Announce Sale of Software License to Qualoptima  Marketwire(Wed, Jul 11)

Thursday, June 21, 2012

     . 
Quture/TCLN Issues Shareholder Letter and Update Marketwire(Thur,  Jun 21)

Tuesday, June 12, 2012

      . Quture International, Inc. / TCLN Announces Pre-Launch Completion of QualOptima Commercial Product Marketwire(Tues, Jun 12)

Monday, May 14, 2012

     .  Quture/TCLN Announces Formation of Subsidiary for European Operations Marketwire(Mon, May 14)

Tuesday, March 27, 2012

     .  Quture International, Inc. / TCLN Announces Successful Completion to QualOptima Product Demonstration. Marketwire(Tues, Mar 27)
  
Thursday, March 15, 2012

        .Techs Loanstar, Inc. Announces Corporate Name Change to Quture International, Inc.Marketwire(Thurs, Mar 15)

Tuesday, December 20, 2011

      .  Quture/TCLN Annousnces First Commercial  Application on Intersystems Platform  Marketwire(Tues, Dec 20)

Thursday, November 10, 2011

Monday, September 26, 2011

Tuesday, September 6, 2011

Tuesday, August 23, 2011

Monday, July 25, 2011

Tuesday, June 28, 2011

Monday, June 27, 2011

 
 






 

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
QUTR
Current Price
Volume:
Bid Ask Day's Range
Wiki
PostSubject
#3801  Sticky Note NEWS OUT http://finance.yahoo.com/news/quture-qutr-announces-qualoptima-physicia PennysRus415 01/20/15 02:32:31 PM
#3832   Retire43, are you and Retirement one and the BIGDADMAC 01/26/15 01:28:12 PM
#3831   I hope they are putting out a good Retire43 01/26/15 11:55:31 AM
#3830   Yes...listed at end of last news release sch100 01/26/15 11:36:45 AM
#3829   That's the PR guys? Retire43 01/26/15 11:15:13 AM
#3828   Talked to Infinity Advisors....very positive on where Q sch100 01/26/15 11:07:30 AM
#3827   Ihub shows OS at 2,285.9M! So it's pretty much Retire43 01/26/15 09:33:31 AM
#3826   Penny2Dime, you seem so persistent on the subject Fido 01/26/15 08:37:18 AM
#3825   What if financial tell us OS is maxed Penny2Dime 01/26/15 08:07:45 AM
#3824   Hope so. Been waiting a long time Tmyz 01/25/15 08:27:02 PM
#3823   When patent news and fins come we will inforthemoney2 01/25/15 08:25:54 PM
#3822   Nobody is pushing the information Tmyz 01/23/15 09:09:20 PM
#3821   I did expect pps at least double or Penny2Dime 01/23/15 12:35:49 PM
#3820   That is the truth. I am sure if BIGDADMAC 01/23/15 12:29:55 PM
#3819   This may become a runaway freight train, just gauvdog 01/23/15 05:54:49 AM
#3818   The story is amazing it just needs more PennysRus415 01/22/15 01:26:49 PM
#3817   This may become a runaway freight train, just BIGDADMAC 01/22/15 12:03:06 PM
#3816   This has so much potential to go big....and sch100 01/22/15 09:33:28 AM
#3815   Maybe this is why LF had a meeting inforthemoney2 01/22/15 09:04:43 AM
#3814   Quture.reminds me of the "little train that could" inforthemoney2 01/22/15 08:36:16 AM
#3813   I think for the most part investors do Retire43 01/21/15 01:18:38 PM
#3812   I stand corrected..Looks like we are getting some inforthemoney2 01/21/15 11:19:00 AM
#3811   Thought for sure we would see some action inforthemoney2 01/21/15 10:52:04 AM
#3810   Yea, if only we could get some investors chance4 01/21/15 10:03:19 AM
#3809   Oh Yea..The excitement is starting to grow.QUTR inforthemoney2 01/21/15 09:37:27 AM
#3808   Yes...and with filings/patents/website follow up with sales/earnings and sch100 01/21/15 08:45:43 AM
#3807   Thats what I was thinking also..Sounds like we inforthemoney2 01/21/15 06:19:39 AM
#3806   For everyone wondering about the website. Tobinn 01/20/15 10:40:59 PM
#3805   Got a feeling we are sitting on a inforthemoney2 01/20/15 09:17:27 PM
#3804   According to teh news looks like 2015 is inforthemoney2 01/20/15 09:08:24 PM
#3803   Yes. This is beginning to come together. Retire43 01/20/15 03:33:40 PM
#3802   Another piece of the puzzle LF is putting together. BIGDADMAC 01/20/15 03:01:22 PM
#3801   NEWS OUT http://finance.yahoo.com/news/quture-qutr-announces-qualoptima-physicia PennysRus415 01/20/15 02:32:31 PM
#3800   Landon's latest tweet: Look at this - @VentureValkyrie BIGDADMAC 01/19/15 06:29:03 PM
#3799   Sounds good brother..I'm sure you will like what inforthemoney2 01/18/15 09:51:13 PM
#3798   Thanks for the replies! Two replies were gauvdog 01/18/15 08:31:27 PM
#3797   Hang in there. there is strong mrnutsandbolts 01/18/15 07:42:10 PM
#3796   I wonder why a month later we have chance4 01/18/15 02:14:35 PM
#3795   On dec 16 th Q was taken off Retire43 01/18/15 02:00:30 PM
#3794   I agree. Tmyz. This week we should see inforthemoney2 01/18/15 01:25:56 PM
#3793   Dog, I've been in for years and have seen Tmyz 01/18/15 10:11:40 AM
#3792   Many here have been in at much higher chance4 01/18/15 09:34:47 AM
#3791   So I purchased a paltry 150000 a few gauvdog 01/18/15 09:14:45 AM
#3790   Thanks info Tmyz 01/17/15 09:11:28 PM
#3789   I know..crazy how a 10 dollar trade can inforthemoney2 01/17/15 03:21:22 PM
#3788   Interesting how a trade valued at around 10 chance4 01/17/15 02:13:29 PM
#3787   Could be a short covering my guess inforthemoney2 01/17/15 11:38:34 AM
#3786   What would be the motivation for this? Tmyz 01/16/15 11:22:39 PM
#3785   Talk about manipulation a 2500 share sell drops inforthemoney2 01/16/15 04:03:18 PM
#3784   Nice 670k slap on the ask..Only 328k left inforthemoney2 01/16/15 03:47:04 PM
#3783   41s up..Qutr inforthemoney2 01/16/15 03:33:06 PM
PostSubject